Prognosis
Heart-Drug Suppliers for Millions Faulted Over Data, Bugs, Dirt
- FDA in March approved generic versions of blood-pressure drugs
- U.S. inspections at companies found extensive quality issues
Drug capsules are pictured on a production line.
Photographer: GERARD JULIEN/AFP/Getty Images
This article is for subscribers only.
Want more news about the future of health care? Sign up here for Bloomberg’s Prognosis newsletter to get great stories delivered to your inbox every Thursday.
A pair of drugmakers in India that the U.S. is counting on to produce generic blood-pressure pills after a far-reaching recall have been faulted by regulators for quality-control issues.